Legal & General Group
PSTX

Legal & General Group’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Legal & General Group’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,514
Closed -$62.5K – 3408
2024
Q4 		$62.5K Sell
6,514
-106
-2% -$553 ﹤0.01% 2755
2024
Q3 		$18.9K Hold
6,620
– – ﹤0.01% 3071
2024
Q2 		$19.3K Buy
6,620
+480
+8% +$1.31K ﹤0.01% 3032
2024
Q1 		$19.6K Hold
6,140
– – ﹤0.01% 2969
2023
Q4 		$20.6K Sell
6,140
-411
-6% -$1.06K ﹤0.01% 3021
2023
Q3 		$15.6K Hold
6,551
– – ﹤0.01% 3125
2023
Q2 		$11.5K Buy
+6,551
New +$16.7K ﹤0.01% 3296
2022
Q2 		– Sell
-2,310
Closed -$10K – 3690
2022
Q1 		$10K Hold
2,310
– – ﹤0.01% 3411
2021
Q4 		$16K Hold
2,310
– – ﹤0.01% 3354
2021
Q3 		$17K Hold
2,310
– – ﹤0.01% 3338
2021
Q2 		$23K Sell
2,310
-1,073
-32% -$9.61K ﹤0.01% 3252
2021
Q1 		$32K Buy
3,383
+1,917
+131% +$18.8K ﹤0.01% 2973
2020
Q4 		$16K Hold
1,466
– – ﹤0.01% 3184
2020
Q3 		$13K Buy
+1,466
New +$16.7K ﹤0.01% 3140

Other funds holding PSTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Legal & General Group's PSTX Position: Q1 2025 in Review

Legal & General Group sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 6,514 shares — an estimated $62.5K sold.

Legal & General Group first reported a position in PSTX in Q3 2020 and held it in 14 quarters. The position peaked at $62.5K in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

  • Legal & General Group reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Legal & General Group sold 6,514 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $62.5K.
  • Legal & General Group first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 14 quarters.
  • Legal & General Group's Poseida Therapeutics, Inc. Common Stock position peaked at $62.5K in Q4 2024.
  • 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Legal & General Group's 13F filing for Q1 2025, filed 15 May 2025.